Business
-
According to Liquidia, the company has reached a settlement with United Therapeutics to end all litigation related to patent infringement by Liquidia’s Yutrepia treprostinil DPI. A United States District Court judge recently ruled that Yutrepia… Read more . . .
-
Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler… Read more . . .
-
A judge in the United States District Court for the District of Delaware has found infringement by Liquidia of two claims included in US Patent No. 11,826,327 (“Treatment for interstitial lung disease”), which was issued… Read more . . .
-
The Cystic Fibrosis Foundation has agreed to invest up to $7.3 million in Ride Therapeutics to support identification of potential delivery vehicles for inhaled genetic therapies for CF. According to the CFF, Ride plans to test millions… Read more . . .
-
Inhaled mRNA developer Ethris has signed an agreement with the European Investment Bank (EIB), and the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA) for a €30 million financing to support clinical development… Read more . . .
-
Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has… Read more . . .
-
Leyden Laboratories has announced that it acquired intranasal RNA therapy developer RIGImmune sometime earlier this year. The company also reported results from a Phase 1 study of RIGImmune’s RIG-101, an intranasal innate immune modulator for… Read more . . .
-
MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… Read more . . .
-
Aurobindo Pharma announced that its newly-acquired US subsidiary Lannett has launched 100/50 mcg and 250/50 mcg strengths of a generic version of Advair Diskus fluticasone propionate / salmeterol xinafoate DPI in the US. Aurobindo notes that… Read more . . .
-
According to ENA Respiratory, the company has received AU$2.98 million in funding from the new Australian “national virtual incubator” Biointelect Venturer, with the funds going to support a Phase 1b study of ENA’s INNA-051 dry powder… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA